litlas
Log inCreate account

Michael J. Duffy

Active 1975–2025

Also published as
Michael J Duffy
119
Papers
23,515
Citations
86
h-index
116
i10-index

Citations

Citations per year for Michael J. Duffy1974: 1 citations1976: 5 citations1977: 9 citations1978: 5 citations1980: 4 citations1981: 1 citations1982: 5 citations1983: 5 citations1984: 2 citations1985: 4 citations1986: 3 citations1989: 4 citations1990: 5 citations1991: 4 citations1992: 15 citations1993: 10 citations1994: 29 citations1995: 23 citations1996: 14 citations1997: 49 citations1998: 52 citations1999: 60 citations2000: 76 citations2001: 86 citations2002: 69 citations2003: 104 citations2004: 104 citations2005: 83 citations2006: 99 citations2007: 122 citations2008: 142 citations2009: 156 citations2010: 158 citations2011: 189 citations2012: 179 citations2013: 149 citations2014: 173 citations2015: 181 citations2016: 141 citations2017: 166 citations2018: 166 citations2019: 636 citations2020: 589 citations2021: 636 citations2022: 553 citations2023: 374 citations2024: 640 citations2025: 270 citations2026: 9 citations1975: no citations, so this year is not shown1979: no citations, so this year is not shown1987–1988: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 1,650 citing papers, 20.2% of this breakdownChina: 1,304 citing papers, 16% of this breakdownGermany: 452 citing papers, 5.5% of this breakdownUnited Kingdom: 423 citing papers, 5.2% of this breakdownItaly: 376 citing papers, 4.6% of this breakdownIndia: 234 citing papers, 2.9% of this breakdownCanada: 227 citing papers, 2.8% of this breakdownFrance: 208 citing papers, 2.6% of this breakdownSpain: 196 citing papers, 2.4% of this breakdownNetherlands: 196 citing papers, 2.4% of this breakdownAustralia: 188 citing papers, 2.3% of this breakdownJapan: 178 citing papers, 2.2% of this breakdown
0%20.2%Other 30.9%

Institutions

Fields

  • Biochemistry, Genetics and Molecular Biology49.3%
  • Medicine39.9%
  • Immunology and Microbiology2.4%
  • Computer Science1.8%
  • Chemistry1.5%
  • Engineering1.3%
  • Other3.8%

Topics

  • Protease and Inhibitor Mechanisms3.7%
  • HER2/EGFR in Cancer Research2.6%
  • Cancer Genomics and Diagnostics2.5%
  • Peptidase Inhibition and Analysis2.3%
  • MicroRNA in disease regulation2.2%
  • Cancer Cells and Metastasis2.2%
  • Other84.5%

Coauthors

All papers

Open in search
  1. MYC as a target for cancer treatment

    Authors: Michael J. Duffy, Shane O’Grady, Minhong Tang, John Crown - Cancer Treatment Reviews 2021 cited by 543

  2. Targeting p53 for the treatment of cancer

    Authors: Michael J. Duffy, Naoise C. Synnott, Shane O’Grady, John Crown - Seminars in Cancer Biology 2020 cited by 350

  3. Prognostic and predictive biomarkers in breast cancer: Past, present and future

    Authors: Andrea Nicolini, Paola Ferrari, Michael J. Duffy - Seminars in Cancer Biology 2017 cited by 430

  4. Biomarkers for prostate cancer: prostate-specific antigen and beyond

    Authors: Michael J. Duffy - Clinical Chemistry and Laboratory Medicine (CCLM) 2019 cited by 275

  5. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM)

    Authors: Michael J. Duffy, Nadia Harbeck, M. Nap, R. Molina, Andrea Nicolini, Elżbieta Senkus, Fátima Cardoso - European Journal of Cancer 2017 cited by 533

  6. CA 15-3: Uses and limitation as a biomarker for breast cancer

    Authors: Michael J. Duffy, Denis Evoy, Enda McDermott - Clinica Chimica Acta 2010 cited by 368

  7. Carcinoembryonic Antigen as a Marker for Colorectal Cancer: Is It Clinically Useful?

    Authors: Michael J. Duffy - Clinical Chemistry 2001 cited by 802

  8. Mutant p53 as a target for cancer treatment

    Authors: Michael J. Duffy, Naoise C. Synnott, John Crown - European Journal of Cancer 2017 cited by 368

  9. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients

    Authors: Michael J. Duffy, John Crown - Clinical Chemistry 2019 cited by 302

  10. Circulating tumor DNA (ctDNA) as a biomarker for lung cancer: Early detection, monitoring and therapy prediction

    Authors: Michael J. Duffy - Tumor Biology 2023 cited by 63

  11. Circulating Tumor DNA as a Biomarker for Monitoring Patients with Solid Cancers: Comparison with Standard Protein Biomarkers

    Authors: Michael J. Duffy, John Crown - Clinical Chemistry 2022 cited by 54

  12. Circulating tumor DNA (ctDNA) as a pan-cancer screening test: is it finally on the horizon?

    Authors: Michael J. Duffy, Eleftherios P. Diamandis, John Crown - Clinical Chemistry and Laboratory Medicine (CCLM) 2021 cited by 53

  13. Mutant p53 in breast cancer: potential as a therapeutic target and biomarker

    Authors: Michael J. Duffy, Naoise C. Synnott, John Crown - Breast Cancer Research and Treatment 2018 cited by 233

  14. Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer

    Authors: Alexandra Canonici, Merel Gijsen, Maeve Mullooly, Ruth Bennett, Noujoude Bouguern, Kasper Pedersen, Neil A. O’Brien, Ioannis Roxanis, Jiliang Li, Esther Bridge, Richard S. Finn, Dennis J. Slamon, Patricia M. McGowan, Michael J. Duffy, Norma O’Donovan, John Crown, Anthony Kong - Oncotarget 2013 cited by 164

  15. MYC as a therapeutic target for the treatment of triple-negative breast cancer: preclinical investigations with the novel MYC inhibitor, MYCi975

    Authors: Minhong Tang, Shane O’Grady, John Crown, Michael J. Duffy - Breast Cancer Research and Treatment 2022 cited by 36

  16. Tumor Markers in Clinical Practice: A Review Focusing on Common Solid Cancers

    Authors: Michael J. Duffy - Medical Principles and Practice 2012 cited by 272

  17. Trastuzumab induces antibody-dependent cell-mediated cytotoxicity (ADCC) in HER-2-non-amplified breast cancer cell lines

    Authors: Denis M. Collins, Norma O’Donovan, Patricia M. McGowan, Finbarr O’Sullivan, Michael J. Duffy, John Crown - Annals of Oncology 2011 cited by 142

  18. Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?

    Authors: Michael J. Duffy, Minhong Tang, Subhasree Rajaram, Shane O’Grady, John Crown - Cancers 2022 cited by 45

  19. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for Use of Tumor Markers in Testicular, Prostate, Colorectal, Breast, and Ovarian Cancers

    Authors: Catharine M. Sturgeon, Michael J. Duffy, Ulf‐Håkan Stenman, Hans Lilja, Nils Brünner, Daniel W. Chan, Richard J. Babaian, Robert C. Bast, Barry L. Dowell, Francisco J. Esteva, Caj Haglund, Nadia Harbeck, Daniel F. Hayes, Mads Holten-Andersen, George G. Klee, R. Lamerz, Leendert H. J. Looijenga, Rafael Molina, Hans Jørgen Nielsen, Harry G. Rittenhouse, Axel Semjonow, Ie‐Ming Shih, Paul Sibley, György Sölétormos, Carsten Stephan, Lori J. Sokoll, Barry Hoffman, Eleftherios P. Diamandis - Clinical Chemistry 2008 cited by 1,134

  20. Metalloproteinases: role in breast carcinogenesis, invasion and metastasis

    Authors: Michael J. Duffy, Teresa Maguire, Arnold Hill, Enda McDermott, N. J. O’Higgins - Breast Cancer Research 2000 cited by 635

  21. Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use

    Authors: Michael J. Duffy, A. van Dalen, Caj Haglund, Lars‐Erik Hansson, Elke Holinski‐Feder, R Klapdor, R. Lamerz, Païvi Peltomäki, C. Sturgeon, Ondřej Topolčan - European Journal of Cancer 2007 cited by 512

  22. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report

    Authors: Michael J. Duffy, Catharine M. Sturgeon, R. Lamerz, Caj Haglund, V.L. Holubec, Rüdiger Klapdor, Andrea Nicolini, Ondřej Topolčan, Volker Heinemann - Annals of Oncology 2009 cited by 379

  23. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer

    Authors: György Sölétormos, Michael J. Duffy, Suher Othman Abu Hassan, René H.M. Verheijen, Bengt Tholander, Robert C. Bast, Katja N. Gaarenstroom, Catharine M. Sturgeon, Johannes M.G. Bonfrèr, Per Hyltoft Petersen, Hugo Troonen, Gian CarloTorre, J Kulpa, Malgorzata Tuxen, Raphael Molina - International Journal of Gynecological Cancer 2015 cited by 263

  24. Drugging “undruggable” genes for cancer treatment: Are we making progress?

    Authors: Michael J. Duffy, John Crown - International Journal of Cancer 2020 cited by 85